1. Home
  2. HITI vs URGN Comparison

HITI vs URGN Comparison

Compare HITI & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HITI
  • URGN
  • Stock Information
  • Founded
  • HITI 2009
  • URGN 2004
  • Country
  • HITI Canada
  • URGN United States
  • Employees
  • HITI N/A
  • URGN N/A
  • Industry
  • HITI
  • URGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • HITI
  • URGN Health Care
  • Exchange
  • HITI Nasdaq
  • URGN Nasdaq
  • Market Cap
  • HITI 187.8M
  • URGN 181.2M
  • IPO Year
  • HITI N/A
  • URGN 2017
  • Fundamental
  • Price
  • HITI $2.35
  • URGN $14.24
  • Analyst Decision
  • HITI Strong Buy
  • URGN Strong Buy
  • Analyst Count
  • HITI 2
  • URGN 8
  • Target Price
  • HITI $4.75
  • URGN $29.00
  • AVG Volume (30 Days)
  • HITI 332.4K
  • URGN 4.1M
  • Earning Date
  • HITI 06-16-2025
  • URGN 08-12-2025
  • Dividend Yield
  • HITI N/A
  • URGN N/A
  • EPS Growth
  • HITI N/A
  • URGN N/A
  • EPS
  • HITI N/A
  • URGN N/A
  • Revenue
  • HITI $398,202,371.00
  • URGN $91,871,000.00
  • Revenue This Year
  • HITI $12.43
  • URGN $36.65
  • Revenue Next Year
  • HITI $11.39
  • URGN $88.35
  • P/E Ratio
  • HITI N/A
  • URGN N/A
  • Revenue Growth
  • HITI 9.22
  • URGN 8.98
  • 52 Week Low
  • HITI $1.57
  • URGN $3.42
  • 52 Week High
  • HITI $3.62
  • URGN $18.15
  • Technical
  • Relative Strength Index (RSI)
  • HITI 55.72
  • URGN 64.26
  • Support Level
  • HITI $2.26
  • URGN $13.55
  • Resistance Level
  • HITI $2.44
  • URGN $14.66
  • Average True Range (ATR)
  • HITI 0.08
  • URGN 0.83
  • MACD
  • HITI 0.01
  • URGN -0.08
  • Stochastic Oscillator
  • HITI 71.19
  • URGN 73.66

About HITI High Tide Inc.

High Tide Inc is a downstream-focused retailer of cannabis products, distributor, and seller of smoking accessories and cannabis lifestyle products. It is a vertically integrated company in the Canadian cannabis market with various brands in its portfolio such as Canna Cabana, Fastendr, Queen of Bud, Grasscity, Daily High Club, Famous Brandz, and others. The company's reportable operating segments are; Bricks and mortar which generates maximum revenue, and E-commerce. Geographically, it derives maximum revenue from its business in Canada followed by the United States of America, and other international markets.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Share on Social Networks: